Given the above OCCAMS findings, it is difficult to use TP53 mutation as a biomarker of adenocarcinoma, as it has also been identified in biopsies from never‐dysplastic patients, who should not progress to adenocarcinoma. The gene discussed is TP53; the disease is adenocarcinoma.